Major trial aims to boost remission rates for seniors with aggressive blood cancer
NCT ID NCT07469046
Summary
This study is comparing two drug combinations for older adults newly diagnosed with a fast-growing blood cancer called acute myeloid leukemia (AML). It will test if adding a third drug (homoharringtonine) to the current standard two-drug therapy (venetoclax and azacitidine) leads to better outcomes. The goal is to see if the three-drug combo helps more patients achieve remission and live longer without the disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
Contact
Conditions
Explore the condition pages connected to this study.